Iovance Biotherapeutics (IOVA)
(Real Time Quote from BATS)
$11.46 USD
-0.08 (-0.69%)
Updated Apr 26, 2024 11:06 AM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
IOVA 11.46 -0.08(-0.69%)
Will IOVA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IOVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IOVA
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
IOVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates
Other News for IOVA
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
First Week of May 31st Options Trading For Iovance Biotherapeutics (IOVA)